Tirilazad mesylate
| Code | Size | Price |
|---|
| TAR-T28978-5mg | 5mg | £1,091.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T28978-50mg | 50mg | £2,143.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T28978-100mg | 100mg | £2,801.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Tirilazad is a lazaroid and potent inhibitor of iron-dependent lipid peroxidation. Tirilazad has shown excellent activity in in vivo models of experimental central nervous system trauma & ischemia. Tirilazad protects brain tissue, and reduces brain damage on animal models. However, the drug fails to treat, and even worsens a stroke when studied on a human being.
CAS:
110101-67-2
Formula:
C39H56N6O5S
Molecular Weight:
720.97
Purity:
0.98
SMILES:
CS(O)(=O)=O.[H][C@@]12CC(C)[C@H](C(=O)CN3CCN(CC3)c3cc(nc(n3)N3CCCC3)N3CCCC3)[C@@]1(C)CC=C1[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
References
1. Bracken MB, Shepard MJ, Holford TR, Leo-Summers L, Aldrich EF, Fazl M, Fehlings M, Herr DL, Hitchon PW, Marshall LF, Nockels RP, Pascale V, Perot PL Jr, Piepmeier J, Sonntag VK, Wagner F, Wilberger JE, Winn HR, Young W. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA. 1997 May 28;277(20):1597-604. PubMed PMID: 9168289.
2. Zhang S, Wang L, Liu M, Wu B. Tirilazad for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2010 Feb 17;(2):CD006778. doi: 10.1002/14651858.CD006778.pub2. Review. PubMed PMID: 20166088.
3. Fleishaker JC, Pearson PG, Wienkers LC, Pearson LK, Moore TA, Peters GR. Biotransformation of tirilazad in human: 4. effect of finasteride on tirilazad clearance and reduced metabolite formation. J Pharmacol Exp Ther. 1998 Nov;287(2):591-7. PubMed PMID: 9808685.
4. Jang YG, Ilodigwe D, Macdonald RL. Metaanalysis of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2009;10(1):141-7. doi: 10.1007/s12028-008-9147-y. Epub 2008 Sep 23. PubMed PMID: 18810661.